Cervical Device Contraception-2 (Nanopaz)

Cervical Device Contraception

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00689494

Acronym

NANOPAZ

Enrollment

Registered

2008-06-03

Start date

2008-06-30

Completion date

2010-05-31

Last updated

2008-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Nanopaz device, Blood progesterone measure in using the device, Delivery progesterone, Progesterone levonorgestrel

Brief summary

Measure blood progesterone by using cervical device contraception.

Detailed description

A very small cervical device that releases small amount of progesterone 20 mcgm/day. The target of the research is to measure blood progesterone by using the cervical device. This small device delivers progesterone by nanotechnology method.

Interventions

OTHERNanopaz contraception device

levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

1 Months to 2 Months

Healthy volunteers

Yes

Inclusion criteria

* 10 healthy women are candidate for hysterectomy

Exclusion criteria

* Women with neoplastic malignancy disease or thrombophylia

Design outcomes

Primary

Measure	Time frame
blood progesterone measure in blood	one to two months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026